Study introduces Reverse Vaccine Development as a strategic approach to identify correlates of protection early in vaccine development against antimicrobial-resistant pathogens, aiming to mitigate risks such as significant phase-III clinical trial failures.
The study evaluates the efficacy of a new quadrivalent mRNA influenza vaccine, finding it to be highly immunogenic and protective in a mouse model. Compared to traditional vaccines, the mRNA-based option offers advantages like reduced production time and elimination of the risk of growth-promoting mutations.